Yoshinobu Saito

Suita, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 145 publications

Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis.

Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis.

Journal: American journal of physiology. Lung cellular and molecular physiology
Published: August 22, 2026

Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer.

Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer.

Journal: The oncologist
Published: May 22, 2026

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer
Published: March 16, 2026

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

Journal: JTO clinical and research reports
Published: February 12, 2026

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.

Journal: Journal of gastroenterology
Published: February 10, 2026

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: PloS one
Published: January 29, 2026

Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.

Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.

Journal: Thoracic cancer
Published: November 12, 2025

Level and sociodemographic correlates of maximum acceptable physical activity increase among Japanese adults.

Level and sociodemographic correlates of maximum acceptable physical activity increase among Japanese adults.

Journal: Global health promotion
Published: October 22, 2025

Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: October 18, 2025

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: October 16, 2025

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.

Journal: PloS one
Published: October 14, 2025

Genome-wide CRISPR screen identifies ACSL3 as a regulator of lipotoxicity and progression of MASLD.

Genome-wide CRISPR screen identifies ACSL3 as a regulator of lipotoxicity and progression of MASLD.

Journal: Hepatology communications
Published: October 02, 2025
Showing 1-12 of 145

Last Updated: 09/26/2026